Analytical task Clause Samples

An Analytical Task clause defines the scope and requirements for performing specific analyses or evaluations within a contract or agreement. It typically outlines the objectives, methodologies, and deliverables expected from the party responsible for the analysis, such as preparing a market study, conducting a risk assessment, or generating a technical report. By clearly specifying these parameters, the clause ensures that both parties understand the expectations and standards for the analytical work, thereby reducing ambiguity and helping to achieve reliable, actionable results.
Analytical task. All concentrations measured with ICP-MS are mean values based on three (n = 3). For lung and olfactory bulb three animals per dose group were examined after 3 and 12 months. After 24 months four animals were examined each per dose group. The mean values of three and four organs each were again calculated as mean value for lung and olfactory bulb, respectively. The results for all organs are shown in table 2. Dose group 0: 0 mg/m³ (control group) Dose group 1: 0.1 mg/m³ Dose group 2: 0.3 mg/m³ Dose group 3: 1 mg/m³ Dose group 4: 3 mg/m³ Table 2: Overview of animals examined on CeO2 organ burden after chronic exposure 601 10 3 months 0 mg/m³ lung, olfactory bulb 602 10 3 months 0 mg/m³ lung, olfactory bulb 603 10 3 months 0 mg/m³ lung, olfactory bulb 611 11 3 months 0.1 mg/m³ lung, olfactory bulb 612 11 3 months 0.1 mg/m³ lung, olfactory bulb 613 11 3 months 0.1 mg/m³ lung, olfactory bulb 621 12 3 months 0.3 mg/m³ lung, olfactory bulb 622 12 3 months 0.3 mg/m³ lung, olfactory bulb 623 12 3 months 0.3 mg/m³ lung, olfactory bulb 631 13 3 months 1 mg/m³ lung, olfactory bulb 632 13 3 months 1 mg/m³ lung, olfactory bulb 633 13 3 months 1 mg/m³ lung, olfactory bulb 642 14 3 months 3 mg/m³ lung, olfactory bulb 643 14 3 months 3 mg/m³ lung, olfactory bulb 604 20 12 months 0 mg/m³ lung, olfactory bulb 605 20 12 months 0 mg/m³ lung, olfactory bulb 606 20 12 months 0 mg/m³ lung, olfactory bulb 614 21 12 months 0.1 mg/m³ lung, olfactory bulb 615 21 12 months 0.1 mg/m³ lung, olfactory bulb 616 21 12 months 0.1 mg/m³ lung, olfactory bulb 624 22 12 months 0.3 mg/m³ lung, olfactory bulb 625 22 12 months 0.3 mg/m³ lung, olfactory bulb 626 22 12 months 0.3 mg/m³ lung, olfactory bulb 634 23 12 months 1 mg/m³ lung, olfactory bulb 635 23 12 months 1 mg/m³ lung, olfactory bulb 636 23 12 months 1 mg/m³ lung, olfactory bulb 644 24 12 months 3 mg/m³ lung, olfactory bulb 645 24 12 months 3 mg/m³ lung, olfactory bulb 646 24 12 months 3 mg/m³ lung, olfactory bulb 607 30 24 months 0 mg/m³ lung, olfactory bulb 608 30 24 months 0 mg/m³ lung, olfactory bulb 199 31 24 months 0.1 mg/m³ lung, olfactory bulb 619 31 24 months 0.1 mg/m³ lung, olfactory bulb 200 31 24 months 0.1 mg/m³ lung, olfactory bulb 627 32 24 months 0.3 mg/m³ lung, olfactory bulb 300 32 24 months 0.3 mg/m³ lung, olfactory bulb 630 32 24 months 0.3 mg/m³ lung, olfactory bulb 637 33 24 months 1 mg/m³ lung, olfactory bulb 638 33 24 months 1 mg/m³ lung, olfactory bulb 639 33 24 months 1 mg/m³ lung, olfactory bulb 400 33 24 mont...
View Source
Analytical task. The task within the deliverable was to determine the concentration of cerium in tissues of lungs and olfactory bulb.
View Source

Related to Analytical task

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be or have been submitted to FDA or other comparable governmental entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, applicable Authorizations, and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and, for studies submitted to regulatory authorities for approval, in all material respects, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete and fairly present the data derived from such studies and trials in all material respects; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes materially call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • TECHNICAL EVALUATION (a) Detailed technical evaluation shall be carried out by Purchase Committee pursuant to conditions in the tender document to determine the substantial responsiveness of each tender. For this clause, the substantially responsive bid is one that conforms to all the eligibility and terms and condition of the tender without any material deviation. The Institute’s determination of bid’s responsiveness is to be based on the contents of the bid itself without recourse to extrinsic evidence. The Institute shall evaluate the technical bids also to determine whether they are complete, whether required sureties have been furnished, whether the documents have been properly signed and whether the bids are in order. (b) The technical evaluation committee may call the responsive bidders for discussion or presentation to facilitate and assess their understanding of the scope of work and its execution. However, the committee shall have sole discretion to call for discussion / presentation. (c) Financial bids of only those bidders who qualify the technical criteria will be opened provided all other requirements are fulfilled. (d) AIIMS Jodhpur shall have right to accept or reject any or all tenders without assigning any reasons thereof.

  • Technology Research Analyst Job# 1810 General Characteristics

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • Supplier Development lf the Buyer identifies problems in supplier performance based on supplier monitoring, he shall initiate improvement measures at the Supplier. The Buyer shall pursue the possibilities of continuous improvement of the Supplier. The supplier audit is a form of supplier development; the exchange of information and experience between the Buyer and the Supplier also serves this purpose.